頁籤選單縮合
題名 | Carlipin藥物使用評估=Drug Utilization Evaluation of Carlipin |
---|---|
作者 | 江仁傑; 張佳惠; 吳秀琴; Chiang, Jen-chieh; Chang, Chia-hui; Wu, Hsiu-chin; |
期刊 | 藥學雜誌 |
出版日期 | 20131200 |
卷期 | 29:4=117 2013.12[民102.12] |
頁次 | 頁122-126 |
分類號 | 418.271 |
語文 | chi |
關鍵詞 | α-glucosidase抑制劑; 第2型糖尿病; 藥物使用評估; Acarbose; |
中文摘要 | 糖利平錠 (Carlipin,學名 Acarbose)是一種腸道內的 α -glucosidase抑制劑,臨床用於第 2型糖尿病之治療。為實際了解降血糖藥品糖利平錠在臨床上的使用情形,此項研究採用院內電腦病例資料庫,取樣自 2012年1月至 3月間,連續使用三個月以上的糖利平錠之糖尿病人者,以審閱電子病歷之方式進行藥物使用評估,希望提供日後更合理的用藥依據。本次評估項目包括健保適應症、治療期間是否有適當的血糖監測、藥物的交互作用及用藥期間副作用的發生情形。 結果顯示有 1%處方不符合健保適應症要求。在藥品交互作用方面,與 β-blockers併用時沒有選用 β 1-selective blockers佔整體 22%;治療期間無採取適當定期血糖監測者佔 13%,另外糖化血色素 (HbA1c)無定期檢查者佔 33%,結果顯示病人的血糖監測與用藥情況應再加強追蹤。 |
英文摘要 | Carlipin (Acarbose), an intestinal α-glucosidase inhibitor, is used for the treatment of type 2 diabetes mellitus. To realize the clinical uses in practice, we did a retrospective drug utilization evaluation (DUE) in a southern district hospital. We enrolled 86 patients who visited our outpatient clinic via our hospital information system database. These patients received Carlipin for at least 3 months from January 2012 to March 2012. We did analysis from different aspects, including the adherence to National Health Insurance guidelines, blood glucose monitorings, drug interactions and side effects. 86 patients were enrolled, and 46 were females. 1% of the prescriptions did not follow National Health Insurance guidelines. 40 patients were prescribed Carlipin with β-blockers, and 22% of these patients did not received β1-selective blockers. During the course of treatments, 13% patients were not checked blood sugar regularly, and 33% were not routinely checked HbA1c. These data imply that glucose monitorings and drug to drug interactions should be followed more intensively. By the way, clinicians should remind patients of the importance of diet controls and exercises. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。